FBLG

FibroBiologics, Inc. FBLG

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-4.12M

Quarter to Jun 30

Free cash flow

$-3.29M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$269.6K total
Cascade Financial Partners, LLC
$103.1K+562.5%
Fund Evaluation Group, LLC
$49.1K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$28.7K+2.3%
VANGUARD CAPITAL MANAGEMENT LLC
$26.3K-59.0%
Qube Research & Technologies Ltd
$23.0KNew
BlackRock, Inc.
$17.3K-26.0%
BARCLAYS PLC
$6.9KNew
VANGUARD FIDUCIARY TRUST CO
$6.0K0.0%
Tower Research Capital LLC (TRC)
$4.5K+927.8%
OSAIC HOLDINGS, INC.
$2.3K+1461.0%
UBS Group AG
$1.0K-81.2%
ROYAL BANK OF CANADA
$1.0K+718.3%
ISLAY CAPITAL MANAGEMENT, LLC
$1600.0%
Grove Bank & Trust
$95New
BNP PARIBAS FINANCIAL MARKETS
$61-3.0%
Allworth Financial LP
$130.0%
See all 16 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FBLG

Earnings Per Share

13fpro.ai/company/FBLG

Loading ratio trend…

FBLG insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About FibroBiologics, Inc. (FBLG): stock profile, AI score and financials

FibroBiologics, Inc. (FBLG) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. FBLG is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), FibroBiologics, Inc. reports net income of $-4.1M, free cash flow of $-3.3M. Top institutional holders of FBLG by reported 13-F value include Cascade Financial Partners, Fund Evaluation Group, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. FBLG trades on the Nasdaq exchange and files with the SEC under CIK 1958777. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBLG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FibroBiologics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1958777 →